Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $167,125.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $9.55, for a total value of $167,125.00. Following the completion of the sale, the chief financial officer directly owned 130,180 shares of the company’s stock, valued at approximately $1,243,219. This represents a 11.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total transaction of $220,000.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Price Performance

Shares of Alpha Tau Medical stock opened at $10.88 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. Alpha Tau Medical Ltd. has a 52-week low of $2.87 and a 52-week high of $11.62. The company has a fifty day moving average of $9.39 and a 200-day moving average of $7.61. The stock has a market capitalization of $982.79 million, a price-to-earnings ratio of -16.24 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Equities research analysts expect that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Trifecta Capital Advisors LLC purchased a new stake in shares of Alpha Tau Medical in the 4th quarter worth about $48,000. Envestnet Asset Management Inc. bought a new position in Alpha Tau Medical in the third quarter worth about $62,000. Principal Financial Group Inc. purchased a new stake in Alpha Tau Medical in the first quarter worth about $132,000. Bank of America Corp DE boosted its position in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after acquiring an additional 21,677 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after acquiring an additional 17,500 shares in the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on DRTS shares. Citigroup boosted their target price on Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Barclays lifted their price target on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Piper Sandler lifted their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.60.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.